FDA warns public not to use certain pregnancy tests due to safety, accuracy issues

The U.S. Food and Drug Administration (FDA) has issued a warning urging consumers not to use certain tests produced by Universal Meditech (UM). The agency's safety communication underscores potential risks associated with multiple UM tests, highlighting questions surrounding their accuracy and safety. 

UM manufactured a range of tests catering to different needs, including pregnancy, ovulation, urinalysis, ketone, and pH tests. These tests were distributed by online platforms and marketed under various brand names by different distributors. A total of 15 different products were flagged as part of the FDA safety warning: 

  • One Step Pregnancy Test  

  • DiagnosUS One Step Ovulation Test  

  • HealthyWiser UriTest 10 Parameter Reagent Test Strips for Urinalysis  

  • HealthyWiser UriTest UTI Test Strips  

  • HealthyWiser KetoFast Ketone Test Strips  

  • HealthyWiser pH-Aware pH Test Strips  

  • To Life hCG Pregnancy Urine Test  

  • Am I Pregnant Pregnancy Midstream Test  

  • DeTec hCG Pregnancy Urine Test  

  • PrestiBio Pregnancy Strips 

  • PrestiBio Rapid Detection Pregnancy Test Midstream 

  • PrestiBio Ovulation Strips 

  • PrestiBio Urinalysis Test Strip 10 Parameters 

  • PrestiBio Ketone Test Strips 

  • PrestiBio Breast Milk Alcohol Test Strips 

Distributors specifically mentioned in the FDA’s warning include AC&C Distribution, HealthyWiser, Home Health US and Prestige Biotech. 

In response, UM has notified the FDA that it has ceased operations and will no longer distribute any tests. This cessation has prompted concerns within the FDA regarding the reliability of UM's products, as the agency cannot confirm their performance. 

The FDA advises consumers not to use or purchase the identified tests, and to discontinue using any tests already obtained. For those seeking accurate results, the FDA suggests using alternative tests. Any issues with these tests should be reported to the FDA's MedWatch Adverse Event Reporting program. 

The full safety communication can be found here

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.